Invesco Pharmaceuticals ETF
Filed by Invesco Exchange-Traded Fund Trust. What this fund reported holding in its latest quarterly NPORT-P. Positions are ordered by share of the fund rather than by size, because that is what separates a conviction from a rounding error.
What it holds
Largest share of the fund first.
| Company | % of fund | Value |
|---|---|---|
| ABTAbbott Laboratories | 5.67% | $26.8M |
| ABBVAbbVie Inc | 5.48% | $25.9M |
| AMGNAmgen Inc | 5.33% | $25.2M |
| JNJJohnson & Johnson | 5.18% | $24.4M |
| MRKMerck & Co Inc | 5.06% | $23.9M |
| LLYEli Lilly and Co | 5.02% | $23.7M |
| GILDGilead Sciences, Inc | 4.53% | $21.4M |
| PFEPfizer Inc | 4.50% | $21.2M |
| LGNDLigand Pharmaceuticals Inc | 3.20% | $15.1M |
| REGNRegeneron Pharmaceuticals Inc | 3.14% | $14.8M |
| BMYBristol-Myers Squibb Co | 2.94% | $13.9M |
| VTRSViatris Inc | 2.83% | $13.3M |
| BIIBBiogen Inc | 2.75% | $13M |
| SUPNSupernus Pharmaceuticals Inc | 2.44% | $11.5M |
| INVAInnoviva Inc | 2.42% | $11.4M |
| UTHRUnited Therapeutics Corp | 2.34% | $11.1M |
Source: NPORT-P filings, via EDGAR. Positions arrive by CUSIP, and only a CUSIP verified against a ticker is kept — so this is what we could match, not everything the fund holds, and the matched value is therefore below the fund's own size. A balance is shares where the filing says `NS` and a principal amount where it says `PA`, which is why it is not labelled shares in both cases.
Follow Invesco Pharmaceuticals ETF by email
Invesco Pharmaceuticals ETF's new holdings reports, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.